← Back to Screener
Soleno Therapeutics, Inc. Common Stock (SLNO)
Price$52.57
Favorite Metrics
Price vs S&P 500 (26W)-20.20%
Price vs S&P 500 (4W)54.45%
Market Capitalization$2.71B
P/E Ratio (Annual)129.91x
All Metrics
P/CF (Annual)57.99x
Book Value / Share (Quarterly)$8.61
P/TBV (Annual)5.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)298.89%
Cash Flow / Share (Quarterly)$0.89
Price vs S&P 500 (YTD)10.90%
Gross Margin (TTM)98.58%
Net Profit Margin (TTM)33.96%
EPS (TTM)$0.16
10-Day Avg Trading Volume11.87M
EPS Excl Extra (TTM)$0.16
EPS (Annual)$0.40
ROI (Annual)4.18%
Gross Margin (Annual)98.58%
Cash / Share (Quarterly)$5.84
P/E Basic Excl Extra (TTM)129.91x
P/E Normalized (Annual)129.91x
ROA (Last FY)3.71%
Revenue Growth TTM (YoY)2850.00%
EBITD / Share (TTM)$0.22
ROE (5Y Avg)-99.63%
Operating Margin (TTM)28.97%
Cash Flow / Share (Annual)$0.89
P/B Ratio6.03x
P/B Ratio (Quarterly)5.52x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)14.15x
Net Interest Coverage (TTM)-63.10x
ROA (TTM)4.61%
EV / EBITDA (TTM)235.64x
EPS Incl Extra (Annual)$0.40
Current Ratio (Annual)5.80x
Quick Ratio (Quarterly)5.44x
3-Month Avg Trading Volume2.70M
52-Week Price Return-24.90%
EV / Free Cash Flow (Annual)57.65x
P/E Incl Extra (TTM)129.91x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$8.52
P/S Ratio (Annual)14.25x
Asset Turnover (Annual)0.34x
52-Week High$90.32
EPS Excl Extra (Annual)$0.40
CapEx CAGR (5Y)48.82%
Tangible BV CAGR (5Y)106.22%
26-Week Price Return-16.21%
Quick Ratio (Annual)5.44x
13-Week Price Return26.55%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)5.80x
Enterprise Value$2,693.651
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)0.08%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)10.97%
Cash / Share (Annual)$5.84
3-Month Return Std Dev86.59%
Net Income / Employee (TTM)$0
ROE (Last FY)4.64%
Net Interest Coverage (Annual)-32.65x
EPS Basic Excl Extra (Annual)$0.40
Receivables Turnover (TTM)5.90x
EV / Free Cash Flow (TTM)57.65x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$0.16
Receivables Turnover (Annual)7.63x
ROI (TTM)5.17%
P/S Ratio (TTM)14.25x
Revenue / Share (Annual)$3.63
Tangible BV / Share (Annual)$8.52
Forward P/E13.31x
Price vs S&P 500 (52W)-54.73%
P/E Ratio (TTM)129.91x
Year-to-Date Return13.54%
5-Day Price Return0.11%
EPS Normalized (Annual)$0.40
ROA (5Y Avg)-49.76%
Net Profit Margin (Annual)10.97%
Month-to-Date Return57.02%
Cash Flow / Share (TTM)$-3.15
EBITD / Share (Annual)$0.22
Operating Margin (Annual)4.94%
LT Debt / Equity (Annual)0.11x
P/CF (TTM)57.99x
ROI (5Y Avg)-97.30%
P/E Excl Extra (TTM)129.91x
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$0.16
P/TBV (Quarterly)5.59x
P/B Ratio (Annual)5.52x
Inventory Turnover (TTM)0.84x
Pretax Margin (TTM)33.96%
Book Value / Share (Annual)$8.61
Price vs S&P 500 (13W)25.87%
Beta-2.52x
P/FCF (Annual)58.08x
Revenue / Share (TTM)$3.20
ROE (TTM)5.90%
52-Week Low$29.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.32
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLNOSoleno Therapeutics, Inc. Common Stock | 14.25x | 2850.00% | 98.58% | — | $52.57 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Soleno Therapeutics is a biopharmaceutical company developing novel treatments for rare diseases. Its lead product candidate, DCCR (Diazoxide Choline), is a proprietary extended-release formulation designed to activate KATP channels in the brain, pancreas, and fat tissue. The company targets underserved patient populations with significant unmet medical needs.